Q2 FY27 Revenue Expected to Cross ₹200 Cr; FY27 Revenue Guidance Raised to ₹800+ Cr & Net Profit Guidance to ₹250+ Cr

Mumbai: Cupid Limited (Cupid, The Company), Bharat’s rapidly growing personal care company with a strong global healthcare franchise, continues to witness strong business momentum in FY27, with Q2 FY27 Total Revenue expected to cross ₹200 Cr.

Driven by sustained momentum across its key business verticals and improved visibility across domestic and international markets, the management has revised its FY27 Revenue Guidance to ₹800+ Cr and Net Profit Guidance to ₹250+ Cr.

Revised FY27 Outlook

Financial YearRevenue GuidanceNet Profit Guidance
FY27₹800+ Cr₹250+ Cr

The FY27 outlook has been revised upward, supported by strong Q2 FY27 business momentum expected to continue and grow through Q3 & Q4 FY27, improved visibility across institutional and private markets, continued expansion of the domestic FMCG business, progress towards imminent operationalization of the Palava facility, and sustained growth across the Company’s healthcare, and personal care portfolio.

Q2 FY27 Operational Highlights

  • Cupid approved conversion of up to 30 lakh warrants of Baazar Style Retail Limited into an equivalent number of equity shares at ₹328.25 per share.
  • Cupid received in-principle approval for a manufacturing venture in South Africa, with the proposed facility aimed at supporting local manufacturing and creating a platform for expansion across Africa and international markets.
  • South African manufacturing initiative to adopt an asset-light model, combining Cupid’s manufacturing expertise with local partner support to create a platform for institutional procurement and wider African market expansion.
  • Cupid strengthened its strategic healthcare partnership with GII Healthcare Investment Limited through an additional USD 5 million follow-on investment.
  • Cupid continues to strengthen its healthcare and Personal Care platform, with an expanding FMCG portfolio and manufacturing capabilities supporting both international B2B healthcare and domestic consumer businesses.
  • Strengthened its position in the capital markets with inclusion in BSE Group ‘A’, NIFTY Small Cap 250 and the FTSE Emerging Markets All Cap Index, alongside its continued focus on governance, compliance and disciplined execution.

Looking Ahead

  • Scale domestic FMCG distribution to deepen Cupid’s presence across modern trade, general trade and pharmacy channels.
  • Operationalise the Palava manufacturing facility to enhance production capacity, flexibility and supply capabilities across domestic and international markets.
  • Expand the healthcare and personal care portfolio through new products, regulatory approvals and wider commercialisation opportunities.
  • Strengthen international healthcare business by expanding institutional, government and private-market opportunities across geographies.
  • Build regional manufacturing platforms through the proposed South African venture, creating a potential base for wider international market expansion.
  • Explore strategic healthcare opportunities through partnerships and investments that complement Cupid’s healthcare and personal care ecosystem.